These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1789 related items for PubMed ID: 15983284

  • 41. Silicone gel breast implant adverse event reports to the Food and Drug Administration, 1984-1995.
    Brown SL, Parmentier CM, Woo EK, Vishnuvajjala RL, Headrick ML.
    Public Health Rep; 1998; 113(6):535-43. PubMed ID: 9847926
    [Abstract] [Full Text] [Related]

  • 42. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden.
    Jacobsson I, Jönsson AK, Gerdén B, Hägg S.
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1039-47. PubMed ID: 19650152
    [Abstract] [Full Text] [Related]

  • 43. Are novel drugs more risky for patients than less novel drugs?
    Olson MK.
    J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240
    [Abstract] [Full Text] [Related]

  • 44. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting.
    Tsong Y.
    J Biopharm Stat; 1995 Mar; 5(1):95-114. PubMed ID: 7613562
    [Abstract] [Full Text] [Related]

  • 45. Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System.
    Wysowski DK, Barash D.
    Arch Intern Med; 1991 Oct; 151(10):2003-8. PubMed ID: 1929688
    [Abstract] [Full Text] [Related]

  • 46. Use of a database computer program to identify trends in reporting of adverse drug reactions.
    Johnston PE, Morrow JD, Branch RA.
    Am J Hosp Pharm; 1990 Jun; 47(6):1321-7. PubMed ID: 2368725
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway.
    Gedde-Dahl A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM.
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):999-1005. PubMed ID: 17457794
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001.
    Kimland E, Rane A, Ufer M, Panagiotidis G.
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):493-9. PubMed ID: 15918163
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior.
    Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M.
    Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
    Schiller LR, Johnson DA.
    Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Infections and human tissue transplants: review of FDA MedWatch reports 2001-2004.
    Wang S, Zinderman C, Wise R, Braun M.
    Cell Tissue Bank; 2007 Apr; 8(3):211-9. PubMed ID: 17278013
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 90.